[Skip to Content]
[Skip to Content Landing]
Citations 0
September 2010

Dopamine Agonist Withdrawal Syndrome: The Apomorphine Solution—Reply

Author Affiliations

Author Affiliations: Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York.

Arch Neurol. 2010;67(9):1155-1156. doi:10.1001/archneurol.2010.221

In reply

We thank Schlesinger and colleagues for their interest in our study on dopamine agonist withdrawal syndrome (DAWS) in Parkinson disease.1 They describe the successful use of apomorphine injections to control short-term withdrawal symptoms in 3 of 5 patients who discontinued use of a dopamine agonist prior to DBS surgery for Parkinson disease. It is unclear whether these transient withdrawal symptoms might have progressed to DAWS if dopamine agonist therapy had not been restarted postoperatively.

First Page Preview View Large
First page PDF preview
First page PDF preview